5Adu D, Cockwell P, Ives NJ, et al. Intrleukin-2-recep- tor monoclonal antibodies in renal transplantation: me- ta-analysis of randomized trial[J]. BMJ, 2003, 326 (7 393): 789-793. 被引量：1
6Sollinger HW. Myeophenolate mofetil for the prevention of acute rejection in primary cadaverie renal allograft recipi- ents[J]. Transplantation, 1995, 60(853):225-232. 被引量：1
7Womer KL, Vella JP, Sayegh MH. Chronic allograft dysfunction: mechanisms and new approaches to thera- py[J]. Semin Nephrol, 2000,20(135) :126-147. 被引量：1
8Neuhaus P, Clavien P, Kittur D, et al. Improced treatment response with basilixinmab immunoprophy- laxis after liver transplantation results from a double blind randomized placebo-controlled [J]. Transplanta- tion, 2004,78(334): 886-891. 被引量：1
9Lawen JG, Davies EA, Mourad G, et al. Randomized double-blind study of immunoprophylaxis with basilim- ah. A chimeric anti-interleukin-2 monlclonal antibody, in combination with mycophenolate nofetil-containing triple therapy in renal transplantation[J]. Transplanta- tion,2003,75(256):37-43. 被引量：1
10Nashan B,Moore R, Amloe P,et al. Randomised trial of basiliximab versus placebo for control of acute cellu- lar rejection in renal allograft recipients [J]. Lancet, 1997,350(9 086):1 193-1 198. 被引量：1
